Bayer has confirmed plans to cut 6100 jobs globally.
Bayer has confirmed plans to cut 6100 jobs globally — 5.5% of its global workforce. The integration of the former Schering AG (Germany) with the pharmaceutical division of Bayer Healthcare is predicted to result in annual savings of €700 million from 2009.
Europe is to be the most affected by the cuts, with a loss of 3150 jobs. In addition, 1000 jobs in the US, 750 jobs in Asia Pacific and Japan, and 1200 jobs in Latin America and Canada are set to go. Of these, approximately 1400 will be in global R&D, and 1850 in production by 2009. Around 21850 positions in central administration and local and regional structures will also be reduced.
"We want to create an internationally successful pharmaceutical company with competitive cost structures," said Werner Wenning, chairman of the Bayer AG group management board and the supervisory board of Bayer Schering Pharma, explaining the motivation behind the cuts. "These essential streamlining measures are to be fairly implemented in a socially acceptable process — balanced across the globe."The measures are intended to "create slimmed down and efficient structures and do away with double functions and overlaps," the company argued in a statement. The goal is to strengthen innovation and growth in the company, thereby increasing profit.
www.bayer.com
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.